Novel Re-engineered L DOPA Probiotic Therapy for Parkinson's Disease
新型重新设计的左旋多巴益生菌疗法治疗帕金森病
基本信息
- 批准号:10618744
- 负责人:
- 金额:$ 40.05万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-01 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAddressAdverse effectsAnabolismAnimal ModelAntiparkinson AgentsAreaBacteriaBenserazideBlood - brain barrier anatomyBradykinesiaBrainCarbidopaChromosomesChronicClinicalCodon NucleotidesCommunitiesComplexComplicationCorpus striatum structureDOPA decarboxylaseDataDevelopmentDiseaseDopaDopamineDopamine ReceptorDoseDrug KineticsDyskinetic syndromeEngineered ProbioticsEngineeringEscherichia coliExhibitsGenerationsGenesGeneticGenetic EngineeringGoalsGoldHealthHumanImpaired cognitionIn SituIn VitroInbred C57BL MiceIowaL-DOPA induced dyskinesiaLeadLegal patentLesionLevodopaMeasuresMixed Function OxygenasesModalityModelingModern MedicineMotorMusNatureNerve DegenerationNeuronsNeurotoxinsOralOral AdministrationOxidopamineOxidoreductaseParkinson DiseasePathway interactionsPatientsPerformancePharmaceutical PreparationsPharmacologic SubstancePhasePlasmaPlasmidsProbioticsProductionQuality of lifeRhamnoseRibosomal RNARodent ModelRotationSystemTabletsTherapeuticTimeTransgenic OrganismsTreatment EfficacyTremorUniversitiesWorkbasebehavioral phenotypingdecarboxylase inhibitordelivery vehicledisease phenotypedopamine replacement therapygut colonizationgut healthgut microbiomehost microbiotaimprovedin vivometagenomic sequencingmicrobialmicrobiomemitopark mousemotor deficitmotor impairmentmotor symptommouse modelneurochemistrynigrostriatal pathwaynovelnovel strategiesnovel therapeuticspharmacokinetics and pharmacodynamicsposture instabilitypre-clinicalpreclinical efficacypreventprobiotic supplementationprobiotic therapypromoterreduce symptomsresponseside effectstandard carestemsuccesstherapeutic developmenttranslational approach
项目摘要
Abstract
The complex and prolonged disease course exhibited by Parkinson’s disease (PD) first starts with non-
motor disturbances and then slowly progresses to mild-to-moderate motor deficits, ultimately inflicting severe
movement impairment and cognitive decline. Dopamine deficiency resulting from nigrostriatal dopaminergic
neuronal damage ultimately manifests as the cardinal extrapyramidal motor symptoms of rigidity, bradykinesia,
tremors, and postural instability. This proposal addresses one of the greatest challenges facing the current anti-
Parkinsonian therapy of dopamine replacement with the dopamine precursor L-DOPA. Currently, oral tablet
dosing of L-DOPA/carbidopa 3-4 times/day remains the most effective and well-tolerated treatment, one that
significantly improves the motor symptoms and quality of life of patients in the early stages of PD. However, due
to its non-continuous, pulsatile delivery of L-DOPA to the brain, long-term L-DOPA administration causes
deleterious side effects, including L-DOPA-induced dyskinesia (LID) among other motor complications, in the
majority of patients. To achieve sustained symptomatic relief without severe L-DOPA-associated motor
complications, including dyskinesia, we propose that systemic delivery of genetically engineered, chromosome-
integrated, and regulatable L-DOPA-producing probiotic bacteria will avoid fluctuations in plasma L-DOPA levels
and provide a more consistent delivery of L-DOPA to the brain where it can be converted to a continuous supply
of dopamine in the nigrostriatal pathway. Thus, we aim to systematically evaluate the treatment feasibility
and efficacy of this novel microbiome-based platform for the continuous delivery of L-DOPA in relieving
motor symptoms without inducing severe dyskinesia. The scientific premise of the work is supported by key
preliminary data demonstrating that: 1) the genetically reengineered, chromosome-integrated, and regulatable
L-DOPA-producing E. coli Nissle 1917 probiotic strain (EcNrhaL-DOPA) efficiently produce L-DOPA both in vitro and
in vivo than the older plasmid-based system, and 2) oral administration of EcNL-DOPA readily colonizes the mouse
gut, achieves a steady-state plasma L-DOPA level that corresponds to the clinically effective plasma level in PD
patients, and increases L-DOPA and dopamine levels in the brain. To further expand our novel preliminary
results, we will pursue the following specific aims: R61 phase (i) determine the dose-response effect of orally
administered EcNrhaL-DOPA on gut colonization as well as its pharmacokinetic and adaptation profiles in both
C57BL and MitoPark mice; R33 phase (ii) determine the therapeutic efficacy of EcNrhaL-DOPA in the MitoPark and
6-OHDA-lesioned mouse models of PD, and (iii) determine whether sustained delivery of microbial L-DOPA
prevents LID in two mouse models of LID. Our novel therapeutic pipeline strategy involving chronic delivery of
probiotic L-DOPA is expected to transform the dopaminergic therapeutic modalities for PD.
摘要
帕金森病(PD)表现出的复杂和延长的病程首先始于非帕金森病。
运动障碍,然后缓慢发展为轻度至中度运动障碍,最终造成严重的
运动障碍和认知能力下降。黑质纹状体多巴胺能引起的多巴胺缺乏症
神经元损伤最终表现为强直,运动迟缓,
震颤和姿势不稳该提案解决了当前反--
用多巴胺前体左旋多巴替代多巴胺的帕金森病治疗。目前,口服片剂
L-DOPA/卡比多巴3-4次/天的剂量仍然是最有效和耐受性良好的治疗,
显著改善PD早期患者的运动症状和生活质量。但由于
由于L-DOPA向大脑的非连续、脉冲式递送,
有害的副作用,包括左旋多巴诱导的运动障碍(LID)以及其他运动并发症,
大多数患者。达到持续的症状缓解,而不会出现严重的左旋多巴相关运动
并发症,包括运动障碍,我们建议全身性递送基因工程,染色体-
整合和可调节的L-DOPA生产益生菌将避免血浆L-DOPA水平的波动
并向大脑提供更稳定的左旋多巴输送,
黑质纹状体通路中的多巴胺。因此,我们的目标是系统地评估治疗的可行性
以及这种新型的基于微生物组的平台用于持续递送左旋多巴以缓解
运动症状而不引起严重的运动障碍。工作的科学前提是关键支撑
初步数据表明:1)基因重组,染色体整合,可调控,
产L-多巴的E.大肠杆菌Nissle 1917益生菌菌株(EcNrhaL-DOPA)在体外和体外均有效地产生L-DOPA,
和2)口服给予EcNL-DOPA容易定殖小鼠
肠,达到稳态血浆L-DOPA水平,其对应于PD中的临床有效血浆水平
患者,并增加L-DOPA和多巴胺在大脑中的水平。为了进一步扩大我们的小说初步
结果,我们将追求以下具体目标:R61阶段(i)确定口服的剂量反应效应
施用EcNrhaL-DOPA对肠道定殖的影响以及其在两种动物中的药代动力学和适应性特征。
C57 BL和MitoPark小鼠; R33阶段(ii)确定EcNrhaL-DOPA在MitoPark和MitoPark小鼠中的治疗功效。
6-OHDA-损伤的PD小鼠模型,和(iii)确定是否持续递送微生物L-DOPA
在两种LID小鼠模型中预防LID。我们的新型治疗管道策略涉及慢性递送
益生菌L-DOPA有望改变PD的多巴胺能治疗方式。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Anumantha Gounder Kanthasamy其他文献
Anumantha Gounder Kanthasamy的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Anumantha Gounder Kanthasamy', 18)}}的其他基金
Novel Reengineered Microbiome-based Biologic Therapy to Treat Cognitive and Behavioral Symptoms of Alzheimer's Disease and Related Dementias
基于微生物组的新型生物疗法可治疗阿尔茨海默病和相关痴呆症的认知和行为症状
- 批准号:
10527152 - 财政年份:2022
- 资助金额:
$ 40.05万 - 项目类别:
Novel Reengineered Microbiome-based Biologic Therapy to Treat Cognitive and Behavioral Symptoms of Alzheimer's Disease and Related Dementias
基于微生物组的新型生物疗法可治疗阿尔茨海默病和相关痴呆症的认知和行为症状
- 批准号:
10677787 - 财政年份:2022
- 资助金额:
$ 40.05万 - 项目类别:
Novel Re-engineered L DOPA Probiotic Therapy for Parkinson's Disease
新型重新设计的左旋多巴益生菌疗法治疗帕金森病
- 批准号:
10688149 - 财政年份:2021
- 资助金额:
$ 40.05万 - 项目类别:
Protein Aggregation and Inflammasome Signaling in Manganese Neurotoxicity.
锰神经毒性中的蛋白质聚集和炎症小体信号传导。
- 批准号:
10508354 - 财政年份:2021
- 资助金额:
$ 40.05万 - 项目类别:
Novel Re-engineered L DOPA probiotic therapy for Parkinsons Disease
新型重新设计的左旋多巴益生菌疗法治疗帕金森病
- 批准号:
10453379 - 财政年份:2021
- 资助金额:
$ 40.05万 - 项目类别:
Novel Re-engineered L DOPA probiotic therapy for Parkinsons Disease
新型重新设计的左旋多巴益生菌疗法治疗帕金森病
- 批准号:
10043372 - 财政年份:2020
- 资助金额:
$ 40.05万 - 项目类别:
Neuroinflammation and microglial Kv1.3 in Parkinsons disease
帕金森病中的神经炎症和小胶质细胞 Kv1.3
- 批准号:
10528896 - 财政年份:2017
- 资助金额:
$ 40.05万 - 项目类别:
Novel Mechanisms of Pesticide-Induced Neurotoxicity
农药引起的神经毒性的新机制
- 批准号:
9906057 - 财政年份:2017
- 资助金额:
$ 40.05万 - 项目类别:
Neuroinflammation and microglial Kv1.3 in Parkinsons disease
帕金森病中的神经炎症和小胶质细胞 Kv1.3
- 批准号:
9921502 - 财政年份:2017
- 资助金额:
$ 40.05万 - 项目类别:
Protein Aggregation and Inflammasome Signaling in Manganese Neurotoxicity
锰神经毒性中的蛋白质聚集和炎症小体信号转导
- 批准号:
9275981 - 财政年份:2016
- 资助金额:
$ 40.05万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 40.05万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 40.05万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 40.05万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 40.05万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 40.05万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 40.05万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 40.05万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 40.05万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 40.05万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 40.05万 - 项目类别:
Research Grant